Compare Danaher Corporation (DHR) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Las Vegas Sands Corp. — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B). The key difference: Danaher Corporation is far larger — about 6.5× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Las Vegas Sands Corp. for 72 Days on average.
| DHR | LVS | |
|---|---|---|
Market Cap | $152.87B | $23.38B |
Volume | 5,228,698 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $69.49 |
52-Week Low | $161.91 | $35.81 |
Typical Hold Time | 69 Days | 72 Days |
Enterprise Value | $175.08B | $35.27B |
Dividend Yield | 0.74% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
LVS trades at $36.10, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 12.59% net margin and consistent revenue growth, reaching $13.02B in 2025. Recent earnings have been mixed, with a Q2 2026 miss after two prior beats. Analyst sentiment remains positive with a 59% buy rating and a $59.78 consensus price target, implying significant upside. The company maintains robust cash flow from operations of $3.02B in 2025.
The outlook for LVS is cautiously optimistic, driven by solid fundamentals and analyst confidence, but weighed by technical weakness and high debt levels. Investment opportunity lies in the substantial discount to price targets, while risks include leverage, Macao regulatory exposure, and volatile earnings. The stock's current valuation multiples, such as a P/E of 13.99, appear attractive if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
